ArticleWorld journal of surgical oncology2026
MicroRNA-563 as a potential biomarker in triple-negative breast cancer: impeding tumor progression by targeting ITGAV and epithelial-mesenchymal transition.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is characterized by its aggressive nature and limited treatment options, which contribute to a poor prognosis. However, the potential role of microRNA-563 (miR-563) in this malignancy remains unclear. This study investigates the tumor-suppressive role of miR-563 and its underlying mechanisms, proposing its potential as a novel biomarker in TNBC.
methodsThe expression of miR-563 was analyzed in clinical samples of TNBC in comparison to healthy controls and non-TNBC cases. Functional assays were conducted using TNBC cell lines. Bioinformatics prediction and luciferase reporter assays identified integrin subunit alpha-V (ITGAV) as a direct target, which was further validated through rescue experiments. Additionally, epithelial-mesenchymal transition (EMT) markers were assessed to elucidate the mechanistic pathway.
resultsMiR-563 was significantly downregulated in TNBC patients, demonstrating an area under the curve (AUC) of 0.895 for diagnosis. This downregulation correlated with advanced disease stage, lymph node metastasis, and poorer progression-free survival. Overexpression of miR-563 resulted in the suppression of TNBC cell proliferation, migration, and invasion. ITGAV was identified as a direct target of miR-563, and rescue experiments indicated a partial reversal of the tumor-suppressive effects of miR-563. Furthermore, miR-563 inhibited EMT, as evidenced by the upregulation of E-cadherin and downregulation of Vimentin.
conclusionsThese findings identify miR-563 as a crucial tumor suppressor and a potential diagnostic predictor in TNBC, operating in part through the ITGAV-mediated pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.